Immunogenicity, safety and consistency of new trivalent inactivated influenza vaccine.
Publication
, Journal Article
Talbot, HK; Keitel, W; Cate, TR; Treanor, J; Campbell, J; Brady, RC; Graham, I; Dekker, CL; Ho, D; Winokur, P; Walter, E; Bennet, J ...
Published in: Vaccine
July 29, 2008
To augment the available influenza vaccine supply, a phase III study was conducted to evaluate the immunogenicity, safety, and consistency of a new trivalent inactivated influenza vaccine manufactured by CSL Limited. Healthy adults (ages 18-64) were randomized to receive either a single dose of TIV from multi-dose vials with thimerosal, TIV from pre-filled syringes without thimerosal, or placebo. Of the TIV recipients, 97.8% achieved a post-vaccination titer > or =40 against H1N1, 99.9% against H3N2 component, and 94.2% against influenza B. Few local or systemic adverse events were noted after vaccination with either TIV presentation. TIV was well tolerated and immunogenic.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Vaccine
DOI
ISSN
0264-410X
Publication Date
July 29, 2008
Volume
26
Issue
32
Start / End Page
4057 / 4061
Location
Netherlands
Related Subject Headings
- Young Adult
- Virology
- Vaccines, Inactivated
- Thimerosal
- Middle Aged
- Male
- Influenza, Human
- Influenza Vaccines
- Influenza B virus
- Influenza A Virus, H3N2 Subtype
Citation
APA
Chicago
ICMJE
MLA
NLM
Talbot, H. K., Keitel, W., Cate, T. R., Treanor, J., Campbell, J., Brady, R. C., … Edwards, K. M. (2008). Immunogenicity, safety and consistency of new trivalent inactivated influenza vaccine. Vaccine, 26(32), 4057–4061. https://doi.org/10.1016/j.vaccine.2008.05.024
Talbot, H Keipp, Wendy Keitel, Thomas R. Cate, John Treanor, James Campbell, Rebecca C. Brady, Irene Graham, et al. “Immunogenicity, safety and consistency of new trivalent inactivated influenza vaccine.” Vaccine 26, no. 32 (July 29, 2008): 4057–61. https://doi.org/10.1016/j.vaccine.2008.05.024.
Talbot HK, Keitel W, Cate TR, Treanor J, Campbell J, Brady RC, et al. Immunogenicity, safety and consistency of new trivalent inactivated influenza vaccine. Vaccine. 2008 Jul 29;26(32):4057–61.
Talbot, H. Keipp, et al. “Immunogenicity, safety and consistency of new trivalent inactivated influenza vaccine.” Vaccine, vol. 26, no. 32, July 2008, pp. 4057–61. Pubmed, doi:10.1016/j.vaccine.2008.05.024.
Talbot HK, Keitel W, Cate TR, Treanor J, Campbell J, Brady RC, Graham I, Dekker CL, Ho D, Winokur P, Walter E, Bennet J, Formica N, Hartel G, Skeljo M, Edwards KM. Immunogenicity, safety and consistency of new trivalent inactivated influenza vaccine. Vaccine. 2008 Jul 29;26(32):4057–4061.
Published In
Vaccine
DOI
ISSN
0264-410X
Publication Date
July 29, 2008
Volume
26
Issue
32
Start / End Page
4057 / 4061
Location
Netherlands
Related Subject Headings
- Young Adult
- Virology
- Vaccines, Inactivated
- Thimerosal
- Middle Aged
- Male
- Influenza, Human
- Influenza Vaccines
- Influenza B virus
- Influenza A Virus, H3N2 Subtype